FABRAZYME can be prescribed for people with Fabry disease, regardless of disease severity, enzyme activity, or type of genetic variation.
Fabrazyme is an enzyme replacement therapy (ERT) that supplies the enzyme that’s missing or deficient in Fabry disease. The fully functional enzyme helps clear GL-3 buildup in your cells.
How Fabrazyme Works
Fabrazyme helps to clear GL-3 buildup by replacing the missing enzyme in Fabry disease.
Watch this video to learn how Fabrazyme works inside the body.
For over 17 years, Fabrazyme has been prescribed to treat people with Fabry disease.
Learn more about Fabry
disease and treatment
A smaller percentage of individuals treated with Fabrazyme experienced a clinically significant event.*
A clinically significant event is defined as the first instance in any of the four categories below, which occurred after the study started.
A smaller percentage of people had heart, kidney, stroke events, or death.
Study design: A randomized, double-blind, placebo-controlled, multinational, multicenter study of 82 patients (72 males and 10 females) with Fabry disease. Patients were 20 to 72 years of age with a median age of 45 years at baseline, a median age of 36 years at Fabry disease diagnosis, and at a median of 10 years at symptom onset.
*Renal, cardiac, or stroke events or death.
Fabrazyme is the only ERT indicated for patients 2 years of age and older that has proven long-term efficacy and safety.
The rate of kidney function decline was studied in Fabrazyme-treated individuals.
estimated difference in the rate of
kidney function decline
The rate of renal function decline was assessed in Fabry disease patients aged ≥16 years. The mean slope of eGFR* was -1.5 mL/min/1.73m2/year in the Fabrazyme-treated group and -3.2 mL/min/1.73m2/year in the untreated group. The mean difference in eGFR between the two groups was 1.7 mL/min/1.73m2/year.
Study design: In a long-term observational study, the rate of decline in renal function (eGFR slope) was assessed in 122 patients with Fabry disease aged 16 years and older treated with Fabrazyme and matched to a historical cohort of untreated patients.
One of the ways your doctor measures kidney function is to monitor your eGFR—a calculation made using a blood test to determine how your kidneys are working. Declining eGFR may indicate a decline in kidney function.
Treatment with FABRAZYME.
Fabrazyme can be given in a number of treatment settings, including:
Talk to your doctor about which treatment setting is right for you.
Make your treatments a priority.
Fabrazyme is an infusion that's given to help prevent the buildup of GL-3. Fabrazyme keeps helping to clear GL-3 as long as you continue treatment.
Follow the Fabrazyme treatment plan prescribed by your doctor, even if you're not experiencing symptoms.